TB-500 side effects: what the research record actually shows

Last updated 2026-07-25

What is TB-500 and is it the same as thymosin beta-4?

TB-500 is the name given to a synthetic peptide built around a fragment of thymosin beta-4, the naturally occurring protein your body already makes in nearly every tissue. They're related, but they are not the same molecule and treating them as interchangeable is where a lot of sloppy sourcing goes wrong. One 2012 paper specifically describes synthesizing and characterizing "the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500" for use as a reference standard in doping detection work ^[1]. That's a fragment, not the full-length native protein. Full-length thymosin beta-4 is 43 amino acids; the actin-binding region that TB-500 is modeled on is much shorter. This distinction matters for side effects because most of what people cite as "TB-500 safety data" is actually native thymosin beta-4 research, or vice versa. The two have overlapping but not identical pharmacology, and nobody has published a dedicated human safety trial on the synthetic fragment sold under the TB-500 name. If you want the fuller comparison of how the two relate and where they diverge, see TB-500 vs BPC-157 for how it stacks up against the other peptide it's almost always paired with.

Has TB-500 been tested for safety in humans?

No controlled human safety trial for TB-500 exists in the published literature as of this writing. What exists instead is a patchwork of animal studies, in vitro wound-healing assays, and analytical chemistry papers written for anti-doping labs, not clinicians. A 2024 study in the Journal of Chromatography B developed methods to quantify TB-500 and its metabolites in rat plasma and in vitro systems, screening for wound-healing activity along the way ^[2]. That's a pharmacokinetics and detection paper, useful for understanding how the compound behaves and breaks down, but it's rats and cell culture, not a phase 1 human trial with adverse event reporting. A 2026 review in the Journal of the American Academy of Orthopaedic Surgeons (Global Research & Reviews) covers therapeutic peptides in orthopaedics generally, including the challenges of translating peptide research like this into clinical use ^[3]. Two other 2026 papers, one a primer for sports medicine physicians in The American Journal of Sports Medicine ^[4] and one a safety and efficacy review in Sports Medicine covering both approved and unapproved peptide therapies for musculoskeletal injury ^[5], both treat TB-500 as a compound still awaiting the kind of trial data that would let a doctor say anything firm about its human safety profile. The honest answer: side effects in humans are not well documented because the studies that would document them haven't been run.

What side effects are actually reported in the studies that exist?

Because almost none of the literature is human trial data, "reported side effects" mostly means observations from animal models, in vitro toxicity screens, and adverse findings noted incidentally in analytical or veterinary contexts. Here's what's actually in the record, not what's assumed. The rat and in vitro study from 2024 focused on metabolite detection and wound-healing screening rather than toxicity endpoints, so it doesn't report a side-effect profile in the way a drug safety trial would ^[2]. Detection-focused papers, including the equine urine and plasma analysis from 2012 ^[6] and the horse plasma work covering seven bioactive peptides in 2013 ^[7], exist because TB-500 shows up in veterinary and equestrian doping control, which tells you something important on its own: this compound is being used in performance contexts serious enough to justify forensic-grade detection methods, years before any human safety data exists. The gerontology review from 2026 covers therapeutic peptides broadly for healthy aging applications, another preclinical-to-translational research area, and doesn't establish a TB-500-specific side effect list either ^[8]. What you're left with is an absence of documented harm alongside an absence of documented safety. That's not reassurance. It's a data gap, and it should be treated as one.

What are the most commonly reported concerns with injectable peptides like this?

Even without TB-500-specific human trials, the broader peptide therapy literature flags a consistent set of practical concerns that apply to any self-administered or compounded injectable peptide, TB-500 included. Injection site reactions (redness, swelling, mild bruising) are the most universally reported issue across peptide categories, simply because these are subcutaneous or intramuscular injections handled outside a hospital setting in most real-world use. Sourcing and purity variability is another: unapproved compounded peptides don't go through the same batch consistency checks as FDA-approved drugs, and the 2026 Sports Medicine review specifically frames its analysis around "approved and unapproved peptide therapies," underscoring that TB-500 sits in the unapproved category with the quality control gaps that implies ^[5]. There's also a category of theoretical concern that shows up in orthopaedic and sports medicine reviews: peptides that promote tissue growth and cell migration, which is the entire mechanism TB-500 is used for, raise unanswered questions about long-term effects on abnormal cell growth. No study in this research pack confirms this happens with TB-500. None rule it out either. The 2026 orthopaedic review explicitly frames "challenges and future directions" for peptide therapeutics in this space, language that signals the field itself sees this as unresolved ^[3]. Finally, sterility and injection technique matter more than people think. A contaminated vial or poor technique causes real, documented harm (abscess, cellulitis) that has nothing to do with the peptide itself and everything to do with handling.

Is TB-500 legal, and does that affect the safety picture?

TB-500 is not FDA-approved for any human use. You won't find it in the Drugs@FDA database of approved drug products ^[9], and no clinical indication exists that a doctor can legally prescribe it for in the way they'd prescribe an approved medication. It also isn't on either FDA bulks list that governs what compounding pharmacies can legally use. The 503A Bulks List (21 CFR 216.23) ^[10] and the 503B Bulks List (21 CFR 216.24) ^[11] define which bulk drug substances licensed compounders may use under section 503A of the Food, Drug, and Cosmetic Act (21 U.S.C. 353a) ^[12]. TB-500 doesn't appear on FDA's current list of bulk drug substances nominated for compounding use either ^[13]. That legal status matters for the safety conversation because it means there's no regulatory floor guaranteeing purity, dosing accuracy, or manufacturing standards the way there is for an approved drug. For a full breakdown of what "not FDA-approved" actually means in practice for sourcing decisions, see is TB-500 FDA approved. Separately, and this matters a lot if you're an athlete: TB-500 (as a form of thymosin beta-4) sits on the World Anti-Doping Agency's Prohibited List under growth factors and related substances. Multiple analytical chemistry papers in this pack exist specifically because anti-doping labs needed methods to detect it, including papers on adsorption effects in doping-relevant peptide testing ^[14], detection strategies for peptidic drugs in sports doping generally ^[15], in vitro metabolic models for peptide hormone drug testing ^[16], screening methods for peptides under 2 kDa by direct urine injection ^[17], and solid-phase extraction methods for small bioactive peptides from human urine ^[18]. That's a lot of forensic firepower pointed at one compound. If you compete under any WADA-code sport, this isn't a gray area.

What about the BPC-157 and TB-500 combination specifically?

TB-500 is almost never sold or discussed on its own anymore, at least not through any legitimate provider-reviewed channel. In practice, it's dispensed as a compounded BPC-157/TB-500 blend, not as a standalone TB-500 product. This is a sourcing reality worth understanding before you dig into side effects, because it changes the calculus: you're not evaluating one peptide's risk profile, you're evaluating two compounds administered together, and the combined side effect picture (whatever it turns out to be, once someone actually studies it) hasn't been separately established either. Both peptides individually sit in the same evidence category described above: preclinical, mechanistically plausible, human-trial-absent. The rationale providers give for pairing them is that BPC-157 and TB-500 are believed to act on tissue repair through different but complementary pathways, angiogenesis and cell migration being a common shorthand. That's a mechanistic hypothesis carried over from separate animal literature on each compound, not a tested combination safety or efficacy claim. TB-500 Co covers this pairing in detail elsewhere on the site, but the safety-relevant takeaway here is simple: if you're trying to isolate "is this TB-500's side effect or the BPC-157's side effect," the current literature can't answer that question for you, because nobody has published a trial designed to answer it.

How does TB-500's side effect evidence compare to other injury-recovery peptides?

Here's how the evidence quality for TB-500 stacks up against the general categories covered in recent orthopaedic and sports medicine peptide reviews. This isn't a ranking of which peptide is "safer," it's a ranking of how much human evidence backs any safety claim at all.

The pattern across every single row is the same. This is a compound that's well characterized analytically (we know how to find it in blood and urine) and poorly characterized clinically (we don't know what it does to a human body over weeks or years of use).

Are there special safety concerns for women, older adults, or people with existing conditions?

No TB-500-specific study in the current literature breaks out safety findings by sex, age group, or comorbidity status. That's a real gap, not a reassurance. For women specifically, questions about menstrual cycle interaction, pregnancy, and any hormone-sensitive tissue growth concern haven't been studied for TB-500 at all in a published human context. If you're researching this specifically, TB-500 in women covers what's known and, more importantly, what isn't. For older adults, the 2026 gerontology review does discuss therapeutic peptides generally for healthy aging mechanisms ^[8], but it's a mechanisms-and-applications review, not a geriatric safety study of this specific compound. Anyone on blood thinners, with a history of cancer, or with active infection should treat the total absence of safety data as a reason for more caution, not less, since tissue growth and angiogenesis promotion (TB-500's proposed mechanism) is exactly the kind of biological activity you'd want closely monitored in those situations.

How should someone weigh the risk if they're still considering it?

Be honest with yourself about what you're actually deciding. You're not choosing between "FDA-approved drug A" and "FDA-approved drug B" with published number-needed-to-harm data. You're choosing whether to use a compounded, non-FDA-approved peptide blend based on animal studies and mechanistic plausibility, in the total absence of human trial safety data. That doesn't automatically mean don't do it. Plenty of things people use daily lack gold-standard trials. But it does mean the responsible move is: work with a provider who reviews your health history before dispensing anything, source from a pharmacy that compounds under proper oversight rather than an unregulated online seller, and don't treat forum anecdotes as a substitute for the fact that this research gap is real and acknowledged in the current medical literature itself [3,4,5]. Storage and handling also matter more than people expect for a compounded peptide, since improper storage can degrade the product or introduce contamination risk that has nothing to do with the peptide's inherent profile. See does TB-500 need to be refrigerated for the specifics. If you go this route, TB-500 Co's position is that the only defensible path is a provider-reviewed one where a compounding pharmacy partner handles the actual dispensing under medical oversight, not a route where you're guessing at sourcing yourself.

Frequently asked questions

What are the most common TB-500 side effects reported?

There's no published human trial reporting a TB-500 side effect list. Injection site redness or swelling is the most commonly flagged concern across injectable peptides generally, but TB-500-specific human adverse event data doesn't exist in the current literature ^[4][5].

Can TB-500 cause cancer or abnormal cell growth?

No study confirms this, and none rules it out either. Because TB-500's mechanism involves promoting cell migration and tissue growth, orthopaedic reviews flag long-term cell growth effects as an open question for the peptide field generally, not a confirmed risk specific to TB-500 ^[3].

Is TB-500 the same as thymosin beta-4?

No. TB-500 is synthesized around a fragment of thymosin beta-4 (specifically the acetylated 17-23 region), not the full 43-amino-acid native protein ^[1]. They share mechanisms but aren't identical molecules, and safety data for one shouldn't be assumed to apply to the other.

Has TB-500 been tested on humans in a clinical trial?

No published human clinical trial for TB-500 exists as of current literature. Available data comes from rat studies, in vitro assays, and analytical chemistry papers built for anti-doping detection, not controlled human safety trials ^[2][3][4].

Is TB-500 banned for athletes?

Yes. TB-500, as a thymosin beta-4-related substance, falls under WADA's Prohibited List. The volume of anti-doping detection research built specifically to find it in urine and plasma reflects how seriously testing bodies treat it ^{[6][7][14][15][16][17][18]}.

Is TB-500 FDA approved?

No. TB-500 doesn't appear in the Drugs@FDA approved products database ^[9], and it isn't on either FDA bulks list (503A or 503B) that governs legal compounding substances ^[10][11]. See is TB-500 FDA approved for the full breakdown.

Can you buy TB-500 as a standalone product?

Through legitimate provider-reviewed channels, no. TB-500 is dispensed as a compounded BPC-157/TB-500 blend, not sold alone. Any source offering a standalone TB-500 vial outside pharmacy compounding oversight should raise sourcing concerns.

Are there different side effects when TB-500 is combined with BPC-157?

Nobody has published a study isolating combined side effects for the BPC-157/TB-500 blend versus each peptide alone. Both compounds individually sit in preclinical-only evidence territory, so a combined human safety profile simply hasn't been established yet.

Does TB-500 show up on a drug test?

Yes, in sports anti-doping testing specifically. Multiple studies detail LC-MS methods to detect TB-500 in urine and plasma in both human and equine doping control contexts ^{[6][7][17][18]}. It's not part of standard workplace drug panels.

Is TB-500 safe for women?

No TB-500 study breaks out safety data by sex. Questions about menstrual cycle effects, pregnancy safety, or hormone-sensitive tissue interactions are unanswered in the current literature. See TB-500 in women for more detail on this specific gap.

What's the biggest unknown about TB-500 safety?

Long-term human safety over weeks or months of repeated use. All current data is short-duration animal work or in vitro screening; nobody has published data on what happens to a human body after sustained TB-500 exposure ^[2][3][5].

Should I be worried about impurities or contamination?

Yes, this is arguably a bigger real-world risk than the peptide's inherent pharmacology. Because TB-500 isn't on FDA's compounding bulks lists ^[10][11], sourcing quality varies a lot, and unregulated sellers carry higher contamination and mislabeling risk than provider-reviewed compounding pharmacies.

Sources

1. Drug Testing and Analysis, 2012 (PMID 22962027): TB-500 is synthesized from the N-terminal acetylated 17-23 fragment of thymosin beta-4, distinct from the full native protein.
2. Journal of Chromatography B, 2024 (PMID 38382158): A 2024 study quantified TB-500 and its metabolites in rat plasma and in vitro systems and screened for wound-healing activity.
3. JAAOS Global Research & Reviews, 2026 (PMID 41490200): A 2026 orthopaedic review covers therapeutic peptides' applications and translational challenges, including TB-500's category.
4. American Journal of Sports Medicine, 2026 (PMID 41476424): A 2026 physician-facing primer covers injectable peptide therapy categories for orthopaedic and sports medicine use.
5. Sports Medicine (Auckland), 2026 (PMID 41966639): A 2026 review evaluates safety and efficacy of approved and unapproved peptide therapies for musculoskeletal injury, grouping TB-500 among unapproved options.
6. Journal of Chromatography A, 2012 (PMID 23084823): TB-500 detection methods were developed for equine urine and plasma doping control by LC-MS.
7. Analytical and Bioanalytical Chemistry, 2013 (PMID 23318763): A 2013 study developed doping control analysis for seven bioactive peptides, including TB-500, in horse plasma.
8. Frontiers in Aging, 2026 (PMID 42021992): A 2026 gerontology review covers therapeutic peptide mechanisms and applications for healthy aging generally.
9. FDA, Drugs@FDA database: TB-500 does not appear as an FDA-approved drug product in the Drugs@FDA database.
10. eCFR, 21 CFR 216.23 (503A Bulks List): The 503A Bulks List defines which bulk drug substances compounding pharmacies may legally use; TB-500 is not on it.
11. eCFR, 21 CFR 216.24 (503B Bulks List): The 503B Bulks List governs outsourcing facility compounding substances; TB-500 is not included.
12. Cornell Law/Legal Information Institute, 21 U.S.C. 353a: Section 503A of the FDCA establishes the legal framework for pharmacy compounding of bulk drug substances.
13. FDA, bulk drug substances nominated for use in compounding: FDA's current list of nominated bulk drug substances for compounding does not include TB-500.
14. Analytical Biochemistry, 2017 (PMID 28887173): A 2017 study examined adsorption effects for doping-relevant peptides including TB-500 in analytical detection workflows.
15. Expert Review of Proteomics, 2014 (PMID 25382550): A 2014 review covers current status and future directions for detecting peptidic drugs and analogs in sports doping.
16. Journal of Peptide Science, 2015 (PMID 25469748): A 2015 study developed in vitro models for metabolic studies of small peptide hormones in sport drug testing.
17. Journal of Separation Science, 2016 (PMID 26578461): A 2016 method simplified screening for peptides under 2 kDa via direct urine injection and ion mobility mass spectrometry.
18. Drug Testing and Analysis, 2016 (PMID 26472487): A 2016 study developed solid-phase extraction methods for small bioactive peptides from human urine for doping analysis.